Ilorasertib

DRUG2 trials

Sponsors

M.D. Anderson Cancer Center, University of Chicago

Conditions

Advanced CancersMetastatic Malignant NeoplasmSolid NeoplasmUnresectable Malignant Neoplasm

Phase 1

Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery

CompletedNCT02540876

University of ChicagoMetastatic Malignant Neoplasm, Solid Neoplasm, Unresectable Malignant Neoplasm

Start: 2015-09-08End: 2019-02-08Updated: 2019-04-22

Phase 2

Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors

TerminatedNCT02478320

M.D. Anderson Cancer CenterAdvanced Cancers

Start: 2016-08-05End: 2022-05-12Updated: 2023-07-17

Related Papers

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

British Journal of Cancer2018-03-1522 citations

Pharmaco-kinetics/dynamics (PK/PD) evaluation and individual patient cross-over studies with growth trajectory assessment to adaptively develop ilorasertib.

Journal of Clinical Oncology2017-05-201 citations